CD33 splicing modulator 1 - Moligand™, 10 mM in DMSO , CAS No.2762547-05-5

CAS: 2762547-05-5 Cat. No.: C1497041 Formula: C₂₅H₂₅FN₆O Molecular Weight: 444.50

GRADE & PURITY Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease.

Specifications

Specifications & Purity

Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Names and Identifiers

Molecular Weight

444.50

Application Protocols

No item-specific, validated protocols are provided for this listing. The following represents general, field-tested practices for small-molecule splicing modulators in cellular assays.

General screening protocol (guidance)

1. Stock solutions: Dissolve in anhydrous DMSO to 10–50 mM. Vortex and, if needed, sonicate gently. Aliquot and store at –80 °C.
2. Working dilutions: Prepare serial dilutions in DMSO, then dilute 1:100–1:1000 into pre-warmed culture media to achieve final DMSO ≤0.1–0.5%.
3. Treatment: Apply to cells expressing CD33. Incubate 6–48 h depending on assay design and transcript turnover.
4. Readouts: Extract RNA; perform RT–PCR/qPCR with exon junction-specific primers for CD33 isoforms. Confirm protein-level changes by flow cytometry or Western blot where applicable.
5. Controls: Include vehicle-only, a known splicing modulator (if available), and non-targeting controls. Consider time-matched and washout conditions to probe reversibility.

Biochemical/biophysical assays

• For splice reporter systems, transfect cells with CD33 minigene constructs and quantify reporter output after treatment.

Documentation

• Record batch/lot, solvent, exact concentrations, and DMSO percentage. For publication, include CoA/SDS and analytical verification of the working stock.

Biological Roles

Item-specific mechanism data are not provided in this listing. The following describes the biological context suggested by the name “CD33 splicing modulator 1.” Treat as general background and confirm applicability to your experiments.

General background (literature/biology)

• CD33 (SIGLEC-3) is a sialic acid-binding immunoglobulin-like lectin expressed on myeloid lineage cells. Alternative splicing of CD33 pre-mRNA can regulate the inclusion of specific exons, producing isoforms with distinct extracellular domains and signaling capability.
• Small-molecule splicing modulators can influence splice site selection by interacting with RNA, RNA-binding proteins, or components of the spliceosome, thereby shifting exon inclusion/exclusion patterns in target transcripts.

Research use scenarios (general)

• Isoform control: Use compounds of this class to interrogate how CD33 exon usage impacts receptor surface expression and downstream signaling in cell models.
• Assay readouts: RT–PCR with exon junction primers, qPCR for isoform-specific quantification, RNA-seq for transcriptome-wide effects, and protein-level assays (flow cytometry, Western blot) to verify functional consequences.
• Selectivity considerations: Off-target splice modulation can occur; integrate orthogonal assays (e.g., splice reporter constructs, rescue with antisense oligos) to validate on-pathway effects.

Compliance

• For research use only. No diagnostic or therapeutic use is implied or permitted.

Buffer Applications

This product is a bioactive small molecule and is not itself a buffering agent. Accordingly, standard buffer recipes and pH ranges are not applicable.

General assay medium considerations (guidance)

• Delivery: Prepare concentrated stocks in DMSO and dilute into cell culture media or biochemical assay buffers, maintaining a consistent vehicle percentage across conditions (commonly ≤0.1–0.5% final DMSO).
• Compatibility: Validate compound stability and solubility in your chosen buffer (e.g., PBS, HEPES, or culture medium with serum). Monitor for precipitation after dilution and during incubation at 37 °C.
• Adsorption: Some hydrophobic compounds adsorb to polystyrene; consider low-binding plates or glass vials when preparing working solutions.

Refer to the SDS and CoA for any item-specific excipients or formulation notes if provided.

Green Alternatives

As a bioactive tool compound, this product’s environmental profile is dominated by the choice of solvents and assay formats rather than by the compound’s own use as a reagent. The following are general, greener-practice considerations for small-molecule screening.

Greener practices (general)

• Solvent minimization: Use microplate formats and miniaturized volumes to reduce DMSO consumption and waste.
• Aqueous-first approach: Where feasible, increase aqueous fraction and reduce high-boiling dipolar aprotics (DMSO/DMF). Validate compound solubility and activity.
• Avoid halogenated wash solvents for routine cleanup; substitute IPA or EtOAc when compatible.
• Energy efficiency: Store master stocks at –80 °C but keep working aliquots at –20 °C to minimize door-open time and dry ice usage, provided stability supports it.

Comparison of solvent choices (general)

• DMSO (baseline): Excellent solvency; high boiling point complicates waste handling.
• Ethanol/IPA: More benign and readily biodegradable; lower solvency and potential assay interference.
• PEG-400/cyclodextrin carriers: Can enhance aqueous delivery; require compatibility checks and may affect biological readouts.

Trade-offs

• Replacing DMSO with greener vehicles may reduce solubility and assay reproducibility. Pilot tests should quantify recovery and potency shifts before broad adoption.

Pharmaceutical Uses

This product is supplied strictly for research use and is not formulated, certified, or approved for any clinical or diagnostic application.

Context for discovery workflows (general)

• Role in early research: Tool compounds that modulate pre-mRNA splicing are used in target validation, phenotypic screening, and mechanism-of-action studies to inform medicinal chemistry programs.
• Formulation in screening: Stock solutions are typically prepared in DMSO; for in vitro assays, working solutions are made by serial dilution into assay media with matched vehicle controls. No pharmacopeial status or excipient role is claimed.

Manufacturing/CMC note

• No GMP, ICH, or pharmacopeial monograph status is indicated for this item. Not specified for this item; refer to CoA/Spec Sheet if additional quality documentation is required for non-clinical GLP studies.

Physical Properties

Only item-specific values listed in the Product Data are binding. Absent values are provided as general/literature guidance and must not be treated as specifications.

Item-specific

• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance for small-molecule screening ligands in this class

• Physical state: Typically solid at ambient temperature, but this item’s form is not specified.
• Solubility: DMSO is commonly used to prepare stock solutions for cell-based assays. If aqueous work is required, dilution from a DMSO stock into buffered media is typical; assess solubility and precipitation visually and by LC–MS.
• LogP, pKa, melting/boiling point, density, and refractive index: Not specified for this item; refer to CoA/Spec Sheet or measure experimentally for your application.

Notes

• For quantitative properties (UV cutoff, water content, residual solvents, metals), no values are provided here. Not specified for this item; refer to CoA/Spec Sheet.
• Before scale-up or sensitive assays, determine solubility limits and stability profiles (e.g., in DMSO at –20 °C and room temperature; in aqueous media at 37 °C) by LC–MS/HPLC.

Quality and Grades

Item-specific

• Grade: Moligand™ (Aladdin Scientific). This denotes inclusion in our small-molecule/tool compound collection intended for research screening, target validation, and mechanistic studies.
• Purity and analytical limits (UV cutoff, water, residual metals/solvents): Not specified for this item; refer to CoA/Spec Sheet.

What Moligand™ typically implies (general description)

• Sourcing/Selection: Tool compounds prioritized for target- or pathway-relevant activity reported in research use contexts.
• QC Expectation: Identity confirmation by MS and/or NMR and chromatographic purity characterization are standard for this line; consult the item’s CoA for exact methods and acceptance criteria.
• Form and Fill: Supplied in small research quantities suitable for plate-based screening and cellular/biochemical assays.

Implications for use

• Chromatographic and spectroscopic background: If using in optical readouts (UV/Vis or fluorescence), determine background absorbance/fluorescence of your solvent system since compound chromophores vary across Moligand™ entries.
• Trace stabilizers/additives: None are listed for this item. Not specified for this item; refer to CoA/Spec Sheet.

Documentation

• For regulated workflows or publication-grade data, obtain and archive the current CoA and SDS for this specific lot.

Reaction and Applications

This product is supplied as a bioactive research tool rather than a synthetic reagent. It is not typically used as a stoichiometric reagent, catalyst, or solvent in preparative organic chemistry.

Research application context (general guidance)

• CD33 splicing modulation: Compounds in this class are used to study alternative splicing of the CD33 transcript in cellular systems, enabling interrogation of exon inclusion/exclusion and downstream protein isoform expression using RT–PCR, RNA-seq, or reporter assays.
• Target/pathway studies: Apply in cell lines or primary cells expressing CD33 to evaluate transcriptional and post-transcriptional consequences of splice modulation, coupled with flow cytometry or immunoblotting for protein-level effects.
• Screening workflows: Suitable for dose–response profiling, time-course studies, and combination experiments with pathway probes. Include orthogonal assays to confirm on-target splicing outcomes.

Non-applicability to synthetic reactions

• Because the compound is intended as a ligand/tool for biological interrogation, standard sections such as “Grignard reactivity” or “cross-coupling utility” do not apply. For chemistry-related work (derivatization, SAR), use the Synthetic Utility and Reaction Conditions sections as high-level planning guidance only.

Reaction Conditions

Not applicable in the conventional synthetic sense: this compound is a biological tool and not supplied for use as a reagent or catalyst.

Assay conditions (general guidance for bioactive small molecules)

• Stock preparation: Dissolve in anhydrous DMSO (e.g., 10–50 mM). Aliquot and store at –80 °C to minimize freeze–thaw.
• Working concentrations: For cell-based assays, initial ranges often span 0.01–30 µM, refined by dose–response curves. Optimize contact time (e.g., 4–48 h) depending on transcript turnover and splicing kinetics. These are literature-style general ranges and are not specifications for this item.
• Controls: Include vehicle controls and, when available, a positive control splicing modulator and non-targeted negative control.
• Readouts: RT–PCR, qPCR with exon junction primers, splice-reporter assays, RNA-seq for transcriptome-wide impact, and protein-level assays to confirm functional consequences.

Stability checks

• Verify compound integrity in DMSO and in the chosen assay matrix over the experiment window by LC–MS or HPLC to rule out degradation or adsorption losses.

Safety and Handling

Authoritative safety information resides in the SDS. The following consolidates what is known from this listing and general best practices for small research molecules.

Item-specific

• GHS Classification: Not specified for this item; refer to SDS.
• Signal Word / H-Statements / Pictograms: Not specified for this item; refer to SDS.
• Storage Conditions: Store at –80 °C.
• Shipped In: Dry ice packs + Cold packs.

General laboratory precautions (not product-specific)

• PPE: Lab coat, nitrile gloves, safety glasses; use a certified fume hood for weighing, dissolving, and aliquoting.
• Avoid inhalation, ingestion, and skin contact. Prevent aerosol generation when opening vials shipped cold.
• Incompatibilities: Until data are available, avoid strong oxidizers, strong acids/bases, and reactive reducing agents.
• First aid (general): In case of skin/eye contact, rinse with water for at least 15 minutes; seek medical attention. If inhaled, move to fresh air. If ingested, rinse mouth; do not induce vomiting; seek medical attention. Always follow institutional procedures and SDS guidance.
• Special risks: Many heteroatom-rich small molecules may be light- or moisture-sensitive and can adsorb to plastics. Minimize freeze–thaw cycles by aliquoting concentrated stocks.

Waste

• Collect organic solutions for disposal as hazardous chemical waste per local regulations.

Solvent Selection

Item-specific solvent data are not provided; the following guidance reflects common practices for small-molecule screening ligands.

Primary choices for stock preparation (general)

• DMSO: Default solvent for bioactive small molecules due to broad solvency, assay compatibility at low final % (commonly ≤0.1–0.5%), and freezing stability. Prepare concentrated stocks (e.g., 10–50 mM) for aliquoting.
• DMF or ethanol: Alternatives when DMSO solubility is limited or when DMSO interferes with assay readouts; verify compatibility with your biology.
• Aqueous buffers: Direct dissolution is often limited; instead, dilute from an organic stock into assay buffer/media with vigorous mixing to avoid precipitation.

Comparative notes (general)

• DMSO vs ethanol: DMSO provides higher solvency and better freeze–thaw robustness; ethanol may be preferable for alcohol-tolerant assays and when lower viscosity is needed. Always include vehicle controls.
• Surfactant-assisted delivery: In select cell assays, ≤0.01% non-ionic surfactant (e.g., Pluronic F-68) can mitigate precipitation; validate for your system.

Practical tips

• Warm and vortex thawed stocks to fully re-dissolve solids. Filter 0.22 µm only if adsorption losses are acceptable and the compound is soluble at the filtration concentration.
• Track final vehicle concentration rigorously; build matched vehicle controls across all conditions.

Storage and Reconstitution

Item-specific

• Storage Conditions: Store at –80 °C.
• Shipped In: Dry ice packs + Cold packs.
• Appearance, stabilizers, and excipients: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for reconstitution and handling

• Reconstitution solvent: Use anhydrous DMSO to prepare concentrated stock solutions (e.g., 10–50 mM), unless otherwise specified by the CoA.
• Aliquoting: Dispense into single-use, low-dead-volume aliquots in inert vials or low-bind tubes to minimize adsorption and freeze–thaw cycles.
• Freeze–thaw: Avoid repeated cycles. Thaw quickly at room temperature, vortex to ensure homogeneity, and immediately return unused portions to –80 °C.
• Light/moisture sensitivity: Protect from light and moisture until more data are available. Work under dry nitrogen/argon if hygroscopicity is suspected.
• Aqueous dilutions: Prepare immediately before use. Verify clarity and absence of precipitation; discard if turbidity or visible solids persist after mixing.

Stability and specifications

• Long-term stability, solution stability, and assay compatibility: Not specified for this item; refer to CoA/Spec Sheet and verify empirically by LC–MS/HPLC for critical applications.

Compliance

• For research use only. Not for human or veterinary use.

Structure and Identity

Item-specific identifiers for this listing are limited. Where not provided below, consult the accompanying CoA/Spec Sheet or request additional documentation.

• SKU: C1497041
• Product Name: CD33 splicing modulator 1 (research tool compound)
• CAS: 2762547-05-5
• Grade: Moligand™
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

• Item-specific structural class: Not specified for this item; refer to CoA/Spec Sheet.

2D structure description (general guidance)

• The common naming “splicing modulator” indicates a small-molecule chemotype typically designed to engage components of the pre-mRNA splicing machinery or to influence splice site selection for a target transcript (here, CD33). Exact ring systems, heteroatom content, and stereochemistry are not specified for this listing and should be confirmed from the CoA/Spec Sheet or an associated structural file.

Identity confirmation

• Recommended analytical confirmation methods (general): 1H/13C NMR, HRMS or LC–MS, HPLC purity profiling, and, where applicable, chiral HPLC. These are general methods; item-specific acceptance criteria are not provided here.

Synthetic Utility

This product is intended as a bioactive tool compound rather than as a synthetic building block. As such, it is not typically deployed as a reagent or intermediate in organic synthesis.

General guidance (when derivatization is desired)

• For SAR or probe development, chemists may pursue analog synthesis or tagging (e.g., biotinylation, photoaffinity handles). Without a disclosed structure, planning must begin with structure release from the CoA/Spec Sheet or inquiry.
• Typical workflows: Establish robust analytical methods (LC–MS, HPLC) for parent tracking; develop convergent routes to modify putative hotspots while maintaining the core scaffold believed to drive splicing modulation.
• Purification: Reverse-phase preparative HPLC is often necessary for polar/heteroatom-rich scaffolds; confirm identity by HRMS and NMR.

Limitations

• No functional group inventory or reactivity map can be provided without structural disclosure. Not specified for this item; refer to CoA/Spec Sheet.

Target Specificity

Item-specific target-binding data are not provided in this listing. The name suggests activity as a “CD33 splicing modulator,” which generally refers to modulation of CD33 pre-mRNA splicing rather than direct binding to the CD33 protein.

General background (not item-confirmed)

• Putative pathway: Pre-mRNA splicing machinery and associated RNA-binding factors that influence exon selection within the CD33 transcript.
• Expected outcome in models: Shift in exon inclusion/exclusion patterns detectable by isoform-specific RT–PCR and downstream changes in CD33 protein isoforms. Magnitude, potency, and selectivity are compound- and system-dependent.

Caveats

• Off-target effects on global splicing are possible for many modulators; transcriptome-wide profiling (RNA-seq) is recommended to assess selectivity.
• Any Ki, EC50, or selectivity ratios are Not specified for this item; refer to CoA/Spec Sheet or primary literature if available for this exact CAS.

Conclusion

• Treat specificity as a testable hypothesis in your system. Incorporate orthogonal methods to confirm that observed phenotypes arise from the intended splice-modulatory mechanism.

Frequently Asked Questions

What is Moligand??

Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2762547-05-5, the molecular formula is C25H25FN6O, and the molecular weight is 444.50 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.